Effects of plant extracts and derivatives on cardiac K < sup > + < /sup > , Nav, and Ca < sub > v < /sub > channels: a review
Nat Prod Res. 2024 Apr 8:1-28. doi: 10.1080/14786419.2024.2337112. Online ahead of print.ABSTRACTNatural products (NPs) are endless sources of compounds for fighting against several pathologies. Many dysfunctions, including cardiovascular disorders, such as cardiac arrhythmias have their modes of action regulation of the concentration of electrolytes inside and outside the cell targeting ion channels. Here, we highlight plant extracts and secondary metabolites' effects on the treatment of related cardiac pathologies on hERG, Nav, and Cav of cardiomyocytes. The natural product's pharmacology of expressed receptors like alph...
Source: Natural Product Research - April 8, 2024 Category: Biochemistry Authors: Insa Seck Samba Fama Ndoye Michelle Vanessa Kamga Kapchoup Filomain Nguemo Ismaila Ciss Lalla Aicha Ba Abda Ba Seynabou Sokhna Matar Seck Source Type: research
Mavacamten: A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy
Cardiovasc Hematol Agents Med Chem. 2024 Apr 5. doi: 10.2174/0118715257283752240325082733. Online ahead of print.ABSTRACTHypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that ...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - April 8, 2024 Category: Cardiology Authors: Ayesha Abdul Qadir Memon Areeba Shamim Sanoober Mirza Muhammad Osama Iyad Naeem Muhammad Calvin R Wei Source Type: research
Effects of multidisciplinary team continuous care model on psychological behavior and quality of life in children with β-thalassemia major
CONCLUSION: The MDT continuous care model can effectively promote mental health in children with β-TM, improve their quality of life, medical satisfaction, ameliorate the degree of anemia in children, reduce the incidence of complications and improve the prognosis; thus, it is worthy of wide clinical application.PMID:38586087 | PMC:PMC10994799 | DOI:10.62347/OBWD7382 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Xiuping Huang Jian Lu Rongxian Huang Qingmei Lu Yanni Luo Xiaoxiao Huang Liqiao An Yuke Chen Source Type: research
Early life stage exposure to fenbuconazole causes multigenerational cardiac developmental defects in zebrafish and potential reasons
Environ Pollut. 2024 Apr 6:123938. doi: 10.1016/j.envpol.2024.123938. Online ahead of print.ABSTRACTWith the increasing use of triazole fungicides in agriculture, triazole pesticides have aroused great concern about their toxicity and ecological risk. The current study investigated the impairments of embryonic exposure to fenbuconazole (FBZ) on cardiac transgenerational toxicity and related mechanisms. The fertilized eggs were exposed to 5, 50 and 500 ng/L FBZ for 72 h, and the larvae were then raised to adulthood in clean water. The adult fish were mated with unexposed fish to produce maternal and paternal F1 and F2 embry...
Source: Environmental Pollution - April 8, 2024 Category: Environmental Health Authors: Ying Zhang Jiaojiao Guo Chen Tang Ke Xu Zihui Li Chonggang Wang Source Type: research
Effects of plant extracts and derivatives on cardiac K < sup > + < /sup > , Nav, and Ca < sub > v < /sub > channels: a review
Nat Prod Res. 2024 Apr 8:1-28. doi: 10.1080/14786419.2024.2337112. Online ahead of print.ABSTRACTNatural products (NPs) are endless sources of compounds for fighting against several pathologies. Many dysfunctions, including cardiovascular disorders, such as cardiac arrhythmias have their modes of action regulation of the concentration of electrolytes inside and outside the cell targeting ion channels. Here, we highlight plant extracts and secondary metabolites' effects on the treatment of related cardiac pathologies on hERG, Nav, and Cav of cardiomyocytes. The natural product's pharmacology of expressed receptors like alph...
Source: Natural Product Research - April 8, 2024 Category: Biochemistry Authors: Insa Seck Samba Fama Ndoye Michelle Vanessa Kamga Kapchoup Filomain Nguemo Ismaila Ciss Lalla Aicha Ba Abda Ba Seynabou Sokhna Matar Seck Source Type: research
Mavacamten: A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy
Cardiovasc Hematol Agents Med Chem. 2024 Apr 5. doi: 10.2174/0118715257283752240325082733. Online ahead of print.ABSTRACTHypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that ...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - April 8, 2024 Category: Cardiology Authors: Ayesha Abdul Qadir Memon Areeba Shamim Sanoober Mirza Muhammad Osama Iyad Naeem Muhammad Calvin R Wei Source Type: research
Effects of multidisciplinary team continuous care model on psychological behavior and quality of life in children with β-thalassemia major
CONCLUSION: The MDT continuous care model can effectively promote mental health in children with β-TM, improve their quality of life, medical satisfaction, ameliorate the degree of anemia in children, reduce the incidence of complications and improve the prognosis; thus, it is worthy of wide clinical application.PMID:38586087 | PMC:PMC10994799 | DOI:10.62347/OBWD7382 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Xiuping Huang Jian Lu Rongxian Huang Qingmei Lu Yanni Luo Xiaoxiao Huang Liqiao An Yuke Chen Source Type: research
Mavacamten: A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy
Cardiovasc Hematol Agents Med Chem. 2024 Apr 5. doi: 10.2174/0118715257283752240325082733. Online ahead of print.ABSTRACTHypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that ...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - April 8, 2024 Category: Cardiology Authors: Ayesha Abdul Qadir Memon Areeba Shamim Sanoober Mirza Muhammad Osama Iyad Naeem Muhammad Calvin R Wei Source Type: research
Effects of multidisciplinary team continuous care model on psychological behavior and quality of life in children with β-thalassemia major
CONCLUSION: The MDT continuous care model can effectively promote mental health in children with β-TM, improve their quality of life, medical satisfaction, ameliorate the degree of anemia in children, reduce the incidence of complications and improve the prognosis; thus, it is worthy of wide clinical application.PMID:38586087 | PMC:PMC10994799 | DOI:10.62347/OBWD7382 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Xiuping Huang Jian Lu Rongxian Huang Qingmei Lu Yanni Luo Xiaoxiao Huang Liqiao An Yuke Chen Source Type: research
Mavacamten: A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy
Cardiovasc Hematol Agents Med Chem. 2024 Apr 5. doi: 10.2174/0118715257283752240325082733. Online ahead of print.ABSTRACTHypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that ...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - April 8, 2024 Category: Cardiology Authors: Ayesha Abdul Qadir Memon Areeba Shamim Sanoober Mirza Muhammad Osama Iyad Naeem Muhammad Calvin R Wei Source Type: research
Effects of multidisciplinary team continuous care model on psychological behavior and quality of life in children with β-thalassemia major
CONCLUSION: The MDT continuous care model can effectively promote mental health in children with β-TM, improve their quality of life, medical satisfaction, ameliorate the degree of anemia in children, reduce the incidence of complications and improve the prognosis; thus, it is worthy of wide clinical application.PMID:38586087 | PMC:PMC10994799 | DOI:10.62347/OBWD7382 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Xiuping Huang Jian Lu Rongxian Huang Qingmei Lu Yanni Luo Xiaoxiao Huang Liqiao An Yuke Chen Source Type: research
Mavacamten: A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy
Cardiovasc Hematol Agents Med Chem. 2024 Apr 5. doi: 10.2174/0118715257283752240325082733. Online ahead of print.ABSTRACTHypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that ...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - April 8, 2024 Category: Cardiology Authors: Ayesha Abdul Qadir Memon Areeba Shamim Sanoober Mirza Muhammad Osama Iyad Naeem Muhammad Calvin R Wei Source Type: research
Effects of multidisciplinary team continuous care model on psychological behavior and quality of life in children with β-thalassemia major
CONCLUSION: The MDT continuous care model can effectively promote mental health in children with β-TM, improve their quality of life, medical satisfaction, ameliorate the degree of anemia in children, reduce the incidence of complications and improve the prognosis; thus, it is worthy of wide clinical application.PMID:38586087 | PMC:PMC10994799 | DOI:10.62347/OBWD7382 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Xiuping Huang Jian Lu Rongxian Huang Qingmei Lu Yanni Luo Xiaoxiao Huang Liqiao An Yuke Chen Source Type: research
Mavacamten: A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy
Cardiovasc Hematol Agents Med Chem. 2024 Apr 5. doi: 10.2174/0118715257283752240325082733. Online ahead of print.ABSTRACTHypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that ...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - April 8, 2024 Category: Cardiology Authors: Ayesha Abdul Qadir Memon Areeba Shamim Sanoober Mirza Muhammad Osama Iyad Naeem Muhammad Calvin R Wei Source Type: research
